Parabolic Drugs Ltd
PARABDRUGSParabolic Drugs Ltd
PARABDRUGSPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
— | -0.04 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.23 | 6.64 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Parabolic Drugs Limited is an integrated, research-based, pharmaceutical manufacturer and exporter, engaged in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Mankind Pharma Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 928.42 | 772.88 | 450.63 | 233.38 | 77.16 | 81.10 | 77.32 | 18.89 | 0.02 | — | ||||||||||
Raw Materials | 800.45 | 691.04 | 391.42 | 209.02 | 59.07 | 64.87 | 64.60 | 34.72 | 6.41 | — | ||||||||||
Power & Fuel Cost | 9.81 | 10.02 | 17.22 | 15.26 | 10.17 | 8.97 | 6.87 | |||||||||||||
Employee Cost | 22.52 | 23.75 | 19.23 | 17.46 | 10.91 | 9.03 | 9.83 | |||||||||||||
Selling & Administrative Expenses | 23.31 | 25.55 | 20.69 | 14.06 | 8.69 | 6.07 | 5.77 | |||||||||||||
Operating & Other expenses | -89.09 | 94.75 | 72.20 | 55.52 | 294.74 | 32.58 | 2.20 | |||||||||||||
EBITDA | 161.42 | -72.23 | -70.13 | -77.94 | -306.42 | -40.42 | -11.95 | -15.83 | -6.39 | — | ||||||||||
Depreciation/Amortization | 30.85 | 55.19 | 68.25 | 73.20 | 67.22 | 53.65 | 34.54 | 22.52 | 21.59 | — | ||||||||||
PBIT | 130.57 | -127.42 | -138.38 | -151.14 | -373.64 | -94.07 | -46.49 | -38.35 | -27.98 | — | ||||||||||
Interest & Other Items | 64.14 | 73.24 | 83.70 | 98.99 | 107.62 | 10.97 | 9.30 | 3.46 | 0.66 | — | ||||||||||
PBT | 66.43 | -200.66 | -222.08 | -250.13 | -481.26 | -105.04 | -55.79 | -41.81 | -28.64 | — | ||||||||||
Taxes & Other Items | 15.23 | -56.17 | -88.28 | 130.32 | 4.43 | 3.05 | 1.76 | -0.41 | 0.00 | — | ||||||||||
Net Income | 51.20 | -144.49 | -133.80 | -380.45 | -485.69 | -108.09 | -57.55 | -41.40 | -28.64 | — | ||||||||||
EPS | 8.27 | -23.35 | -21.62 | -61.47 | -78.47 | -17.46 | -9.30 | -6.57 | -4.63 | — | ||||||||||
DPS | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | ||||||||||
Payout ratio | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Parabolic Drugs Ltd | -1.19 | -0.04 | — |
Sun Pharmaceutical Industries Ltd | 45.62 | 6.51 | 0.74% |
Mankind Pharma Ltd | 62.83 | 12.55 | — |
Cipla Ltd | 28.94 | 4.45 | 0.88% |
Price Comparison
Compare PARABDRUGS with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
PARABDRUGS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 24, 2012
Dividend/Share
₹0.25
Ex DateEx Date
Sep 24, 2012
Cash Dividend
Ex DateEx DateSep 19, 2011
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2011
Rs 1,626 Crore Money Laundering Case: Ashoka University Co-Founders Sent To 5 Days Remand
Bank Fraud: ED Arrests Two Promoters, CA Of Parabolic Drugs In Money Laundering Case
Have nothing to do with CBI’s investigation of co-founders: Ashoka University
Parabolic Drugs reports standalone net loss of Rs 0.06 crore in the December 2020 quarter
BRIEF-Parabolic Drugs Says Shares Of Co Cancelled Without Any Payout To Shareholders
Parabolic Drugs reports standalone net loss of Rs 7.22 crore in the March 2020 quarter
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged